Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 19/20 | 0.48 |
| ▸ | PLK2 | Q9NYY3 | 15/20 | 0.48 |
| ▸ | BRD4 | O60885 | 4/20 | 0.47 |
| ▸ | TAF1 | P21675 | 2/20 | 0.47 |
| ▸ | PLK3 | Q9H4B4 | 12/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18261942 | 1.00 | PLK1 (0.48) | PLK1PLK2BRD4TAF1PLK3 | |
| SCHEMBL1527197 | 0.87 | PLK1 (0.61) | PLK1PLK2BRD4TAF1PLK3 | |
| SCHEMBL10320062 | 0.87 | PLK1 (0.61) | PLK1PLK2BRD4TAF1PLK3 | |
| SCHEMBL376094 | 0.87 | PLK1 (0.61) | PLK1PLK2BRD4TAF1PLK3 | |
| SCHEMBL337816 | 0.86 | PLK1 (0.48) | PLK1PLK2BRD4TAF1PLK3 | |
| SCHEMBL14310496 | 0.86 | PLK1 (0.48) | PLK1PLK2BRD4TAF1PLK3 | |
| SCHEMBL6840311 | 0.85 | PLK1 (0.58) | PLK1PLK2BRD4TAF1PLK3 | |
| SCHEMBL12345547 | 0.84 | PLK1 (0.46) | PLK1PLK2BRD4TAF1PLK3 | |
| SCHEMBL2028362 | 0.82 | PLK1 (0.55) | PLK1PLK2BRD4TAF1PLK3 | |
| SCHEMBL2028361 | 0.82 | PLK1 (0.55) | PLK1PLK2BRD4TAF1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160347750-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| CN-105939607-A | Dihydropteridinone derivatives and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2016-09-14 | — | — | CN | disclosed |
| US-20090312336-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312336-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312336-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| WO-2007135374-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312336-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | QDPR, PLK2, PFKP | PLK1 235/4885PLK2 2/4885BRD4 4692/4885 |
| US-20160347750-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | PLK1 2859/4885PLK2 2094/4885BRD4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.